Zhouyuan Du

Dr. Zhouyuan Du


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in iScience
Verified
Journal Article
Open access
ZDZhouyuan Du
Zhouyuan Du
QZQun Zhang
Qun Zhang
XXXingxing Xiang
Xingxing Xiang
WLWei Li
Wei Li
QYQinglin Yang
Qinglin Yang
TLTao Liu
Tao Liu
Pancreatic cancer is one of the most malignant types of cancer, and despite recent advances in treatment, prognosis remains extremely poor. The most common site of pancreatic cancer metastasis is the liver. Elucidating the molecular mechanisms of pancreatic cancer progression and liver metastasis is essential for improving patients’ survival. Ribonucleotide reductase subunit M2 (RRM2) has been linked to many types of cancers and is associated with tumor progression. However, the role of RRM2 in the liver metastasis of pancreatic cancer is still unclear. In this study, RRM2 was found to promote the malignant biological behavior of pancreatic cancer and enhance its liver metastasis. Further studies on the downstream molecular mechanisms of RRM2 revealed that RRM2 stabilizes YBX1, upregulates TGFBR1, and activates the TGF-beta pathway to promote pancreatic cancer progression and liver metastasis. In summary, these results suggest that RRM2 may be an effective therapeutic target for pancreatic cancer liver metastasis.

28 February 2024 in Heliyon
Verified
Journal Article
Open access
KLKe Liu
Ke Liu
CWCongbing Wei
Congbing Wei
HYHaixin Yu
Haixin Yu
QZQun Zhang
Qun Zhang
ZDZhouyuan Du
Zhouyuan Du
Pancreatic cancer is a highly aggressive malignancy of the digestive system, with occult onset, rapid progression, and poor prognosis. The genetic heterogeneity of pancreatic cancer contributes to its highly malignant biological behavior. HMGA2 is overexpressed in tumors and is known to regulate tumor progression in various cancers through the HMGA2-IGF2BP2 axis, but its role and mechanism in pancreatic cancer remain unclear. In this study, we demonstrated that HMGA2 promotes pancreatic cancer progression. We further revealed that HMGA2 upregulates IGF2BP2, which stabilizes APLP2 mRNA via m6A modification, thereby promoting pancreatic cancer progression. These results indicate that HMGA2/IGF2BP2/APLP2 signaling axis regulates the progression of pancreatic cancer.

13 August 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
XGXun Guo
Xun Guo
WLWei Li
Wei Li
ZXZhou Xu
Zhou Xu
QYQinglin Yang
Qinglin Yang
ZDZhouyuan Du
Zhouyuan Du
TLTao Liu
Tao Liu
Background Gallbladder cancer is recognized as one of the most aggressive malignancies within the biliary system. Usually, the substantial part of patients are diagnosed at advanced stages, often with metastases to distant organs. In cases of metastatic gallbladder adenocarcinoma, the potential benefit of primary tumor resection (PTR) in improving patient prognosis remains an unresolved issue that warrants further investigation. Patients and methods We collected data to identify patients diagnosed with gallbladder cancer and concurrent metastases to the liver, lungs, bones, brain, or distant lymph nodes between 2004 and 2021 from the Surveillance, Epidemiology, and End Results (SEER) database. The impact of primary tumor resection (PTR) on overall survival (OS) and cancer-specific survival (CSS) was evaluated using the Cox proportional hazards model. Kaplan-Meier survival curves were generated for additional clarity. Subgroup analyses were also conducted to identify patient groups that might have a longer survival period from PTR. Results A total of 1968 patients diagnosed with metastatic gallbladder adenocarcinoma at the time of initial presentation between 2004 and 2021 were included in the analysis. Among these, liver metastasis was the most frequent site of metastasis (n = 1695, 86.12%). Of the total cohort, 600 patients (30.49%) underwent PTR, and these patients demonstrated a significant improvement in both OS (0.679 [0.612–0.752], P < 0.001) and CSS (0.690 [0.619–0.768], P < 0.001). Notably, PTR was associated with reduced overall mortality in patients with isolated liver or distant lymph node metastases (liver metastasis: 0.690 [0.612–0.778], P < 0.001; distant lymph node metastasis: 0.498 [0.324–0.763], P < 0.001), as well as reduced cancer-specific mortality (liver metastasis: 0.698 [0.616–0.791], P < 0.001; distant lymph node metastasis: 0.522 [0.332–0.820], P = 0.003). In addition, patients with one or two metastatic organs who underwent PTR experienced a similar reduction in both overall mortality (1 metastatic organ: 0.691 [0.619–0.771], P < 0.001; 2 metastatic organs: 0.623 [0.434–0.895], P = 0.005) and cancer-specific mortality (1 metastatic organ: 0.700 [0.624–0.785], P < 0.001; 2 metastatic organs: 0.643 [0.439–0.940], P = 0.013). Conclusion These results demonstrate that primary tumor resection (PTR) may prolong life expectancy of patients with certain subtypes of metastatic gallbladder adenocarcinoma. Consequently, these findings offer valuable insights and guidance for the management of metastatic gallbladder adenocarcinoma, particularly in selecting patients who may benefit from surgical intervention.